Linden LLC

Greg Divis Joins Linden as Executive-in-Residence

June 25, 2015 | For Immediate Release

CHICAGO, Illinois (June 25, 2015) – Linden Capital Partners, a Chicago-based private equity firm with $1.3 billion in assets under management focused exclusively on healthcare, today announced the addition of Greg Divis as Executive-in-Residence.  Mr. Divis has partnered with Linden to identify and acquire pharmaceutical assets and platform businesses. Mr. Divis, who has more than 25 years of experience in the pharmaceutical industry, was most recently President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women’s health. At Lumara, Mr. Divis led the successful turnaround and transformation of the business resulting in a series of transactions culminating in the successful sale to AMAG Pharmaceuticals for total proceeds of up to $1.1 billion.

“We are excited to build a team with Greg to identify and build specialty pharmaceutical platforms,” said Linden President and Managing Partner Tony Davis.  “Partnering with proven operators is core to Linden’s strategy, and Greg’s leadership, vision, and track record make him an ideal partner for the Linden team.”

“Joining Linden’s pharmaceutical sector effort provides the opportunity to buy and build specialty pharmaceutical assets and platforms with an exceptional partner,” commented Mr. Divis. “I have spent the last ten years leading cultural transformations and building businesses and look forward to leveraging that experience with Linden’s expertise, network, and cadre of executive talent supporting me.”

Prior to Lumara, Mr. Divis held general management, sales, marketing and business development roles at Schering Plough and Sanofi-Aventis. Mr. Divis is a graduate of the University of Iowa.


About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm with $1.3 billion in assets under management focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.